MYASTHENIA GRAVIS

This study tests a new treatment called KYV-101, made from a patient's own immune cells, for people with generalized myasthenia gravis that hasn't improved with standard therapies. About 66 participants will receive either KYV-101 or continue their usual immunosuppressive drugs. …

This study tests a new drug, IM-101, in adults with myasthenia gravis, a condition causing muscle weakness. The trial has two parts: first, checking safety and dosing in people with a specific antibody type, then testing effectiveness in broader groups. Participants must be on st…

This early-phase study tests a new treatment called anitocabtagene autoleucel (anito-cel) for people with generalized myasthenia gravis, a condition that causes muscle weakness. Anito-cel is a type of CAR-T cell therapy that targets BCMA, a protein on certain immune cells. The st…

This early-phase study tests a new treatment called CC-97540, which uses a patient's own immune cells modified to target and attack harmful immune cells in people with relapsing or progressive multiple sclerosis (MS) or refractory myasthenia gravis (MG). The main goals are to che…

This study tests whether nipocalimab works better than efgartigimod for people with generalized myasthenia gravis, a condition where the immune system attacks nerve-muscle connections, causing weakness. About 115 adults will receive one of the two drugs to see which better contro…

This study is testing an experimental drug called nipocalimab in children aged 2 to 18 who have generalized myasthenia gravis, a condition that causes muscle weakness. The goal is to see if the drug can safely lower certain immune proteins (IgG) that contribute to the disease and…

This study looks at whether giving the drug ravulizumab early, after standard treatments, can help people with a severe myasthenia gravis crisis recover faster in the intensive care unit. About 30 adults in France will be observed for 6 months. The goal is to see if it reduces ti…

This study tests an experimental drug called nipocalimab in about 199 adults with generalized myasthenia gravis, a condition that causes muscle weakness. Participants receive either nipocalimab or a placebo to see if the drug improves daily activities like talking, chewing, and b…

This study is testing how safe and effective different drug combinations are for people with myasthenia gravis, a condition that causes muscle weakness. Researchers want to find treatments that reduce side effects and improve quality of life. About 70 adults with generalized MG a…

This early-stage study is testing a new treatment called KITE-363 for people with autoimmune neurologic diseases like multiple sclerosis, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy that have not responded to standard therapies. KITE-363 uses a patien…

This early-phase study tests a new treatment using specially engineered immune cells (CAR T-cells) that target two proteins, CD19 and BCMA, in up to 12 adults with severe autoimmune diseases affecting the brain and nerves, such as multiple sclerosis and myasthenia gravis. The mai…

This study tests whether adding empasiprubart to the standard treatment efgartigimod can further improve symptoms in people with generalized myasthenia gravis (gMG) who still have muscle weakness. About 70 adults with a specific antibody type (AChR-Ab positive) will receive the c…

This study is testing a new treatment called Zilucoplan in 55 French patients with myasthenia gravis, an autoimmune disease that causes muscle weakness. The goal is to see if the drug improves muscle strength and quality of life over three months, while also checking for side eff…

This early-stage study tests a new treatment called CD19-BCMA CAR-T for people with refractory generalized myasthenia gravis, a condition where the immune system attacks nerve-muscle connections, causing severe weakness. The therapy uses a patient's own immune cells, modified to …

This study tests the drug rozanolixizumab in 40 Chinese adults with generalized myasthenia gravis, a condition that causes muscle weakness. The main goal is to see if the drug improves daily activities after one treatment cycle. Participants receive the drug and are monitored for…

This study is testing whether whole-body electrical muscle stimulation (WB-EMS) can help adults with neuromuscular diseases like ALS, muscular dystrophy, and myasthenia gravis exercise safely. Because these conditions make normal exercise difficult, WB-EMS uses electrical pulses …

This study tests an experimental drug called NMD670 in 84 adults with myasthenia gravis who have specific antibodies (AChR or MuSK). Participants take one of three doses or a placebo twice daily for 21 days. The goal is to see if the drug safely reduces muscle weakness and daily …

This study tests if aerobic exercise or cognitive behavioral therapy can reduce fatigue in people with myasthenia gravis. 60 adults with stable MG will be randomly assigned to one of these treatments or usual care. The goal is to see if these approaches improve fatigue and qualit…

This study looks at whether light or moderate intensity exercise is safe and helpful for people with myasthenia gravis, a condition that causes muscle weakness. Twenty adults will join a 12-week exercise program, doing small group workouts three times a week. Researchers want to …

This study is creating a registry of people with myasthenia gravis, a condition that causes muscle weakness. Researchers will collect blood and stool samples from 800 adults to use in future studies. The goal is to better understand the disease, not to test a new treatment.

This study explores whether artificial intelligence can help standardize tongue diagnosis in traditional Chinese medicine for myasthenia gravis, a chronic muscle weakness condition. Researchers will compare tongue images from 100 participants—half with myasthenia gravis and half …

This study will use smartphone recordings to measure common symptoms of myasthenia gravis, like slurred speech, voice changes, arm fatigue, and droopy eyelids. Researchers will compare 225 people with and without the condition to see if phone data can tell them apart. The goal is…

This study looks at why people with myasthenia gravis (MG) feel short of breath, even during rest or sleep. Researchers will use breathing tests, sleep studies, and questionnaires in 50 adults with MG to better understand the causes. The goal is to improve treatment and quality o…

This study follows about 279 pregnant or breastfeeding women who have taken efgartigimod for myasthenia gravis or CIDP. Researchers will monitor mothers, fetuses, and infants for any health issues, including birth defects. The goal is to better understand the drug's safety during…

This study follows about 680 adults with generalized myasthenia gravis to see how safe efgartigimod is over time. Some participants will take the drug, while others will not. Researchers will compare serious infections and other side effects between the two groups.